GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million

3 months ago 63
Under the deal, Alfasigma volition summation rights to develop, manufacture and commercialize linerixibat.
Read Entire Article
  1. Homepage
  2. Health
  3. GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million

Related

Zyn can be marketed as safe alternative to cigarettes, FDA says

Zyn can be marketed as safe alternative to cigarettes, FDA s...

3 hours ago 1
Draining your lymphatic system

Draining your lymphatic system

9 hours ago 1
How to treat bloodshot eyes

How to treat bloodshot eyes

9 hours ago 1

Popular

Ronaldo shines as Portugal deliver 5-0 thrashing of Uzbekistan and Engand suffer 0-0 draw to Ghana

Ronaldo shines as Portugal deliver 5-0 thrashing of Uzbekist...

6 days ago 20
SoftBank’s Son Sets Bold Net Asset Value Target on Promise of ‘Super AI’

SoftBank’s Son Sets Bold Net Asset Value Target on Promise o...

6 days ago 19
All the world's a robot-staging ground for tech entrepreneurs building 'physical AI'

All the world's a robot-staging ground for tech entrepreneur...

6 days ago 19
'The Blair Witch Project’ movie reboot will haunt cinemas in 2027

'The Blair Witch Project’ movie reboot will haunt cinemas in...

6 days ago 19
Asian stocks are mixed after big tech sell-off

Asian stocks are mixed after big tech sell-off

6 days ago 17
About Us · Contact Us · Privacy Policy ·

© DISQUS CLUB 2026. All rights are reserved